How many HAE
trade-offs are too many?
Advances in long-term prophylactic treatments for hereditary angioedema (HAE) have reduced the frequency of attacks and enabled significant advances in patient care.1 In spite of this, many patients modify their lifestyle and fail to report mild attacks, with an ongoing impact on daily living.2-8 Does accepting attacks and daily trade-offs really equate to control?2,5,7,8
Patient-focused care in HAE continues to evolve2
Exploring newer technologies
The launch of C1 esterase inhibitor therapies in 2008 marked a significant advancement in patient care.1,9 More recently, therapeutic modalities expanded with novel monoclonal antibodies and small molecule prophylactic therapies.10,11 Now, ongoing discovery continues.2,12
Uncovering ongoing impact
While advances in long-term prophylactic treatments have reduced the frequency of attacks, patients may still experience an emotional and physical toll from the disease, including those who rarely have attacks.3,5
Stay informed
Sign up to receive updates about HAE, including resources for your patients and clinical information from Ionis.